These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 15784360

  • 1. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A, Wendel HP, Azevedo R, Ziemer G.
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
    [Abstract] [Full Text] [Related]

  • 2. Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation.
    Kanemitsu S, Nishikawa M, Onoda K, Shimono T, Shimpo H, Yazaki A, Tanaka K, Shiku H, Yada I.
    J Thorac Cardiovasc Surg; 2003 Aug; 126(2):428-35. PubMed ID: 12928640
    [Abstract] [Full Text] [Related]

  • 3. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 4. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 5. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ, Taatjes DJ, Sobel BE.
    Cardiovasc Res; 2000 Jan 14; 45(2):437-46. PubMed ID: 10728364
    [Abstract] [Full Text] [Related]

  • 6. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A, Voss R.
    Thromb Res; 2006 Jan 14; 117(3):307-14. PubMed ID: 15894353
    [Abstract] [Full Text] [Related]

  • 7. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC, Kühnel G, Kemkes-Matthes B, Pralle H, Voss R, Fareed J.
    J Lab Clin Med; 2000 Mar 14; 135(3):247-55. PubMed ID: 10711863
    [Abstract] [Full Text] [Related]

  • 8. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK, Whitaker DA, Sobel BE, Schneider DJ.
    Thromb Res; 2004 Mar 14; 113(1):27-34. PubMed ID: 15081562
    [Abstract] [Full Text] [Related]

  • 9. Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia.
    Straub A, Schiebold D, Wendel HP, Azevedo R, Dietz K, Ziemer G.
    Thromb Res; 2008 Mar 14; 122(3):383-9. PubMed ID: 18304613
    [Abstract] [Full Text] [Related]

  • 10. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
    Straub A, Wendel HP, Dietz K, Schiebold D, Peter K, Schoenwaelder SM, Ziemer G.
    Thromb Haemost; 2008 Mar 14; 99(3):609-15. PubMed ID: 18327411
    [Abstract] [Full Text] [Related]

  • 11. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec 14; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 12. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression.
    Steiner S, Seidinger D, Huber K, Kaun C, Minar E, Kopp CW.
    Arterioscler Thromb Vasc Biol; 2003 Sep 01; 23(9):1697-702. PubMed ID: 12869353
    [Abstract] [Full Text] [Related]

  • 13. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
    Peter K, Straub A, Kohler B, Volkmann M, Schwarz M, Kübler W, Bode C.
    Am J Cardiol; 1999 Sep 01; 84(5):519-24. PubMed ID: 10482148
    [Abstract] [Full Text] [Related]

  • 14. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
    Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL, Michelson AD.
    J Am Coll Cardiol; 2004 Jun 16; 43(12):2319-25. PubMed ID: 15193700
    [Abstract] [Full Text] [Related]

  • 15. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L, Alves VL, Phillips DR.
    Circulation; 2003 Mar 04; 107(8):1123-8. PubMed ID: 12615789
    [Abstract] [Full Text] [Related]

  • 16. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia.
    Mak KH, Kottke-Marchant K, Brooks LM, Topol EJ.
    Thromb Haemost; 1998 Dec 04; 80(6):989-93. PubMed ID: 9869172
    [Abstract] [Full Text] [Related]

  • 17. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
    Chakrabarti S, Clutton P, Varghese S, Cox D, Mascelli MA, Freedman JE.
    Thromb Res; 2004 Dec 04; 113(3-4):225-33. PubMed ID: 15140587
    [Abstract] [Full Text] [Related]

  • 18. Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.
    Bertram U, Moser M, Peter K, Kuecherer HF, Bekeredjian R, Straub A, Nordt TK, Bode C, Ruef J.
    J Thromb Thrombolysis; 2002 Dec 04; 14(3):197-203. PubMed ID: 12913399
    [Abstract] [Full Text] [Related]

  • 19. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Pieper K, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD.
    Am Heart J; 2001 Nov 04; 142(5):790-8. PubMed ID: 11685164
    [Abstract] [Full Text] [Related]

  • 20. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
    Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL.
    J Am Heart Assoc; 2013 May 15; 2(3):e000026. PubMed ID: 23676293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.